Drug intelligence / Profile preview

2-chloro-5-(3-chloro-phenyl)-6-[(4-cyano-phenyl)-(3-methyl-3H-imidazol-4-yl)-methoxymethyl]-nicotinonitrile

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is an experimental small molecule with the chemical formula C25H17Cl2N5O and a molecular weight of approximately 474.34 g/mol. It is not approved for use in any country and has no known clinical indications or patents. There are no reported clinical trials involving this compound, and its mechanism of action, pharmacological class, or therapeutic application have not been described in the available literature[1][2]. The structure contains a nicotinonitrile core substituted with chloro, cyano, phenyl, and imidazole groups.

Other names: DB06953DB-06953DB 06953

Beyond the preview

Go deeper on 2-chloro-5-(3-chloro-phenyl)-6-[(4-cyano-phenyl)-(3-methyl-3H-imidazol-4-yl)-methoxymethyl]-nicotinonitrile.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-chloro-5-(3-chloro-phenyl)-6-[(4-cyano-phenyl)-(3-methyl-3H-imidazol-4-yl)-methoxymethyl]-nicotinonitrile.

Explore the full profile